Roche has announced that Health Canada has approved Kadcyla (trastuzumab emtansine or T-DM1), under priority review, as a single agent for the treatment of people with HER2-positive metastatic breast cancer (mBC) who received both prior treatment with Herceptin (trastuzumab) and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. HER2-positive metastatic breast cancer is a particularly aggressive form of the disease. Women with HER2-positive mBC are at an increased risk of their disease worsening due to the cancer's hard-to-treat nature.  For more details, go to: http://www.newswire.ca/en/story/1223743/health-canada-approves-kadcylatm-trastuzumab-emtansine-for-t...